Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...
The research field of 'cellular IRESes' lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated ...
Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated ...
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.0, a high estimate of $47.00 ...
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
The Hospital for Sick Children. "Newly uncovered mechanism could drive next-gen cystic fibrosis treatments." ScienceDaily. ScienceDaily, 13 March 2025. <www.sciencedaily.com / releases / 2025 / 03 / ...
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback